Bayer Schering Pharma Kicks Off Life Quality Improvement Program For Bone Metastasis In Cancer Patients
Bayer Schering Pharma and Chinese Anti-Cancer Association recently kicked off the "dandelion program", which aims to promote the widespread adoption of the consensus on bone metastasis in malignant tumor and bone-related diseases diagnosis. The program will bring international updates of standardized treatment concepts to 2,000 clinical physicians to enrich their clinical experience in cancer treatment such as palliative treatment skills for active cancer symptoms and pain relief. At the same time, it will strengthen the capability of tumor patients and their relatives to identify false medical information and to understand relevant anti-cancer knowledge. (Click here for more - Chinese language)
More from Archive
More from Scrip
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.